Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/Ecstasy) in synaptosomes: Evidence for a presynaptic localization involving the serotonin transporter (SERT)

Neuropsychopharmacology

Volumn 19, Issue 4, 1998, Pages 265-277

  Kramer, H Kenneth ^a   Poblete, Jose C ^b   Azmitia, Efrain C ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Calcium; Ecstacy; Release; Reverse uptake; Second messenger

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CALCIUM ION; FLUOXETINE; IPSAPIRONE; KETANSERIN; PHORBOL DIBUTYRATE; PROTEIN KINASE C; SEROTONIN 1A AGONIST; SEROTONIN 2 AGONIST; SEROTONIN ANTAGONIST; SEROTONIN TRANSPORTER;

ANIMAL CELL; ARTICLE; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SCATCHARD PLOT; SECOND MESSENGER;

ANIMALS; CALCIUM; CEREBRAL CORTEX; FEMALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; P-CHLOROAMPHETAMINE; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGENTS; SYNAPTOSOMES;

EID: 0031753117     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00027-X     Document Type: Article

References (66)

1. Appel NM, Contrera J, DeSouza EB (1989): Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: Evidence from immunocytochemical studies. J Pharamacol Exp Ther 249:928-943
2. 2+-dependent toxicity linked to release. Brain Res 510:97-103
3. 3H-5-HT from CNS synaptosomes. In Scriabine A, Janis RA, Triggle DJ (eds), Drugs in Development. Branford, CT, Neva Press, pp 437-446
4. Battaglia G, Brooks BP, Kulsakdinun C, DeSouza EB (1988a): Pharmacological profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol - Mol Pharm Sec 149:159-163
5. Battaglia G, Yeh EB, DeSouza E (1988b): MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29:269-274
6. Benowitz LI, Perrone-Bizzozero NI, Finklestein SP (1987): Molecular properties of the growth-associated protein GAP-43 (B-50). J Neurochem 48:1640-1647
7. Berger UV, Grzanna R, Molliver ME (1992a): The neurotoxic effects of p-chloroamphetamine in rat brain are blocked by prior depletion of serotonin. Brain Res 578:177-185
8. Berger UV, Gu XF, Azmitia EC (1992b): The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol - Mol Pharm Sec 215:153-160
9. 2 receptors and serotonergic axons in rat neocortex. Brain Res 453: 315-328
10. Commins DL, Vosmer G, Virus RM, Wollverton WL, Schuster CR, Seiden LS (1987): Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to the rat brain. J Pharmacol Exp Ther 241:338-345
11. Conn PJ, Sanders-Bush E (1985): Serotonin-simulated phosphoinositide turnover: Mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions. J Pharmacol Exp Ther 234:195-203
12. Conn PJ, Sanders-Bush E (1986): Regulation of serotonin-stimulated phosphoinositide hydrolysis: Relation to the serotonin 5-HT2 binding site. J Neurosci 6:3669-3675
13. Farfel GM, Vosmer GL, Seiden LS (1992): The N-methyl-D-asparate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Brain Res 595:121-128
14. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995): Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurosci 15:5476-5485
15. Fischette CT, Nock B, Renner K (1987): Effects of 5,7-DHT on serotonin{-1} and serotonin{-2} receptors throughout the rat central nervous system using quantitative autoradiography. Brain Res 421:263-279
16. Gandhi VC, Jones DJ (1991): G-protein modulation of 3H-serotonin release through the L-type calcium channel. Ann NY Acad Sci 635:455-458
17. Giambalvo CT (1992a): Protein kinase C and dopamine transport - 1. Effects of amphetamine in vivo. Neuropharmacology 31:1201-1210.
18. Giambalvo CT (1992b): Protein kinase C and dopamine transport - 2. Effects of amphetamine in vitro. Neuropharmacology 31:1211-1222
19. Gott AL, Mallon BS, Paton A, Groome N, Rumsby MG (1994): Rat brain glial cells in primary culture and subculture contain the delta, epsilon, and zeta subspecies of protein kinase C as well as the conventional subspecies. Neurosi Lett 171:117-120
20. Gu XF, Azmitia EC (1993): Integrative transporter-mediated releases from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur J Pharmacol - Mol Pharm Sec 235:51-57
21. Harrington MA, Shaw K, Zhong P, Ciaranello RD (1994): Agonist-induced desensitization and loss of high-affinity binding sites of stably expressed human 5-HT1A receptors. J Pharmacol Exp Ther 268:1098-1106
22. Hekmatpanah CR, Peroutka SJ (1990): 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methyldioxymethamphetamine and related agents. Eur J Pharmacol - Mol Pharm Sec 177:95-98
23. Hirst WD, Rattray MAN, Price GW, Wilkin GP (1994): Expression of 5-HT1A, 5-HT2A, and 5-HT2C receptors on astrocytes. Soc Neurosci Abstr 20:1547
24. Insel TR, Battaglia G, Johannessen JN, Marra S, DeSouza EB (1989): 3,4-methylenedioxymethamphetamine ("Ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 249:713-720
25. Johnson MP, Conarty PF, Nichols DE (1991): 3H-Monoamine releasing and inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol - Mol Pharm Sec 200:9-16
26. Johnson MP, Hoffman AJ, Nichols DE (1986): Effects of the enantiomers of MDA, MDMA, and related analogues on 3H-serotonin and 3H-dopamine release from the superfused rat brain slices. Eur J Pharmacol - Mol Pharm Sec 132:269-276
27. Kagaya A, Mikuni M, Kusumi I, Yamamoto H, Takahashi K (1990): Serotonin-induced acute desensitization of serotonin 2 receptors in human platelets via a mechanism involving protein kinase C. J Pharmacol Exp Ther 255:305-311
28. Kokotos Leonardi ET, Azmitia EC (1994): MDMA (Ecstasy) inhibition of MAO type A and type B: Comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:231-238
29. Kramer HK, Azmitia EC (1994): Is protein kinase C activation a key step in MDMA-induced toxicity of serotonergic neurons? CPDD Abstract 144:273
30. Kramer HK, Poblete JC, Azmitia EC (1995): 3,4-methylenedioxymethamphetamine ("Ecstasy") promotes the translocation of protein kinase C (PKS): Requirement of viable serotonin nerve terminals. Brain Res 680:1-8
31. Kramer HK, Poblete JC, Azmitia EC (1997): The activation of protein kinase C by 3,4-methylenedioxymethamphetamine (MDMA) occurs through stimulation of serotonin receptors and transporter. Neuropsychopharmacology 17:117-129
32. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951): Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
33. 2+-dependent protein kinase C isozymes. Biochemistry 34:3446-3454
34. Malberg JE, Malis RW, Sabol KE, Seiden LS (1994): Both ketanserin and alpha-methyl-para-tyrosine may protect against MDMA neurotoxicity by producing a hypothermic response in the rat. CPDD Abstract 56:213
35. Mamounas LA, Molliver ME (1988): Evidence for dual serotonergic projections to neocortex: Axons from the dorsal and median raphe are differentially viable to the neurotoxin p-chloroamphetamine. Exp Neurol 102:23-36
36. Manev H, Costa E, Wroblewski JT, Guidotti A (1990): Abusive stimulation of excitatory amino acid receptors: A strategy to limit neurotoxicity. Fed Am Soc Exper Biol 4: 2789-2797
37. Manev H, Favaron M, Alho H, Bertolino M, Guidotti A, Costa E (1988): Gangliosides and NMDA-sensitive glutamate receptor antagonists prevent glutamate neurotoxicity via different mechanisms. Soc Neurosci Abstr 14:747
38. 2+ influx elicited by glutamate: Role in neuronal death. Mol Pharmacol 36:106-112
39. Masliah E, Yoshida K, Shimahama S, Gage Fh, Saitoh T (1991): Differential expression of protein kinase C isozymes in rat glial cell cultures. Brain Res 549:106-111
40. Meller E, Bohmaker K, Goldstein M, Friedhoff A (1985): Inactivation of D1 and D2 dopamine receptors by N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: Selective protection by neuroleptics. J Pharmacol Exp Ther 233: 656-662
41. 2+-requiring proteinase. Proc Natl Acad Sci 82:6435-6439
42. Miller KJ, Hoffman BJ (1994): Adenosine A3 receptors regulate serotonin transport via nitric oxide and cGMP. J Biol Chem 269:27351-27356
43. Munson PJ, Rodbard D (1980): Ligand: A versatile computerized approach for characterization of ligand binding systems. Analyt Biochem 107:220-239
44. Nash JF (1990): Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 47:2401-2408
45. Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GK (1982): Effects of certain hallucinogenic amphetamine analogues on the release of 3H-serotonin from rat brain synaptosomes. J Med Chem 25:530-535
46. O'Hearn E, Battaglia G, DeSouza EB, Kuhar MJ, Molliver ME (1988): Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonin axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803
47. 2+-uptake into rat brain synaptosomes. Ann NY Acad Sci 635:438-442
48. Pierce PA, Peroutka SJ (1988): Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex. Neurosci Lett 95:208-212
49. Poblete JCP, Azmitia EC (1995): Activation of glycogen phosphorylase by 3,4-methylenedioxymethamphetamine in astrocyte-rich primary glial cultures: Role of the 5-HT2A receptor. Brain Res 680:9-16
50. Pu C, Vorhees CV (1995): Protective effects of MK-801 on methamphetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: An immunohistochemical study. Synapse 19:97-104
51. Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice I, Blakely RD (1997): Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci 17:45-57
52. Quik M, Azmitia E (1983): Selective destruction of the serotonergic fibers of the fornix-fimbria and cingulum bundle increases 5-HT, but not 5-HT-2 receptors in rat midbrain. Eur J Pharmacol - Mol Pharm Sec 90:377-384
53. Ricaurte GA, DeLanney LE, Weiner SG, Langston JW (1988): Toxic effect of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration. Brain Res 446:165-168
54. Rudnick G, Wall SC (1992a): p-chloroamphetamine induces serotonin release through serotonin transporters. Biochemistry 31:6710-6718
55. Rudnick G, Wall SC (1992b): The molecular mechanisms of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci 89:1817-1821
56. Sanders-Bush E, Strenaka LR (1978): Immediate and long-term effects of p-chloroamphetamine on brain amines. Ann NY Acad Sci 305:208-221
57. Schmidt CJ (1987): Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1-7
58. Schmidt CJ, Levin TA, Lovenberg W (1987): In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36:747-755
59. Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990): Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 529:85-90
60. Schmidt CJ, Taylor VL, Abbate GM, Nieduzak TR (1991): 5-HT-2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. J Pharmacol Exp Ther 256:230-235
61. Schmidt CJ, Black CK, Taylor VT, Fadayel GM, Humphreys TM, Nieduzak TR, Sorensen SM (1992): The 5-HT2 receptor antagonist, MDL 28, 133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine. Eur J Pharmacol - Mol Pharm Sec 220:151-159
62. 3H-monoamines into synaptosomes of different regions of rat brain. Biochem Pharmacol 36:2297-2303
63. 2+ release in Chinese hamster ovary (CHO) cells coexpressing dihydropyridine and ryanodine receptors. J Gen Physiol 109:619-631
64. Takagishi Y, Rothery S, Issberner J, Levi A, Severs NJ (1997): Spatial distribution of dehydropyridine receptors in the plasma membrane of guinea pig cardiac myocytes investigated by correlative confocal microscopy and label-fracture electron microscopy. J Electron Micros 46: 165-170
65. Wang H-Y, Friedman E (1990): Central 5-hydroxytryptamine receptor-linked protein kinase C translocation: A functional postsynaptic signal transduction system. Mol Pharmacol 37:75-79
66. Zhang L, Coffey LL, Reith MEA (1997): Regulation of the functional activity of the human dopamine transporter of protein kinase C. Biochem Pharmacol 53:677-688